Skip to main content
Beximco Pharmaceuticals Ltd. logo

Beximco Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · BXP ISIN · US0885792061 LEI · 213800IMBBD6TIOQGB56 IL Manufacturing
Open in API
Filings indexed 125 across all filing types
Latest filing 2021-07-26 Regulatory Filings
Country BD Bangladesh
Listing IL BXP

About Beximco Pharmaceuticals Ltd.

https://www.beximcopharma.com

Beximco Pharmaceuticals Ltd. is a manufacturer of generic drugs and active pharmaceutical ingredients (APIs). The company produces a broad portfolio of over 500 products across various therapeutic categories, with a focus on providing access to affordable medicines. It has established a strong market differentiation through a range of high-tech, specialized products, including metered-dose and dry powder inhalers. Serving numerous emerging and developed markets globally, its manufacturing facilities are accredited by major international regulatory authorities, including those of the USA, European Union, Australia, and Canada.

Recent filings

Filing Released Lang Actions
FDA approval for muscle relaxant drug Baclofen
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's 'Reach' service, announcing that Beximco Pharmaceuticals has received US FDA approval for a new drug (Baclofen). It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement (RPA) for a separate document. As it is a general corporate announcement regarding business operations and regulatory milestones, it falls under the 'Regulatory Filings' (RNS) category.
2021-07-26 English
Update on the supply of COVID-19 vaccine
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Beximco Pharmaceuticals regarding the status of a COVID-19 vaccine supply agreement. It provides a business update on operational challenges and contractual status rather than a formal financial report, proxy, or meeting material. As it is a general regulatory announcement that does not fit into more specific categories like M&A or dividend notices, it is classified as a Regulatory Filing (RNS).
2021-07-07 English
Q3 Financial Results
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for the third quarter and nine months ended 31 March 2021 for Beximco Pharmaceuticals Ltd. It includes detailed consolidated financial statements, such as the Statement of Financial Position, Statement of Profit or Loss, and Statement of Changes in Equity. While it is distributed via an RNS (Regulatory News Service) header, the content provides substantive financial data and analysis for an interim period, qualifying it as an Interim/Quarterly Report rather than a mere announcement or certification. 9M 2021
2021-04-30 English
Update on the supply of COVID-19 vaccine
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Beximco Pharmaceuticals regarding a supply update for COVID-19 vaccines. It discusses operational delays due to export controls and mentions the upcoming release of financial results. Since it is a general regulatory announcement that does not fit into specific categories like earnings releases or financial reports, it is classified as a Regulatory Filing (RNS).
2021-04-28 English
Second Price Monitoring Extn
Regulatory Filings Classification · 100% confidence The document is a short, automated notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Second Price Monitoring Extension' for a security. It does not contain financial statements, management reports, or specific corporate governance disclosures, but rather serves as a technical market notice. As it is a standard regulatory announcement that does not fit into the specific categories like M&A, dividends, or director dealings, it falls under the RNS (Regulatory Filings) category.
2021-03-24 English
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is a short notification from the London Stock Exchange's RNS (Regulatory News Service) regarding a 'Price Monitoring Extension' for Beximco Pharmaceuticals Ltd. It is a technical market notice regarding trading parameters rather than a financial report, management update, or corporate action. As it does not fit into specific categories like dividends, M&A, or director dealings, it falls under the general regulatory filing category.
2021-03-24 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.